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Abstract
Cancer is a multifactorial disease in which cell types lost their capability to regulate
growth, proliferation, and cell death pathways, causing the uncontrolled proliferation
of tumor cells. Cell death pathway is supported by the operation of the p53–Mdm2-
negative feedback loop that has a central role to prevent the development of tumor
cells. Under severe DNA damage, this loop takes the control of the apoptotic pathway
and activates Bax, which, in turn, activates the caspase cascade to produce the death
of the injured cell. However, events like Mdm2 overexpression or the suppression of
caspase-9 gene can block the transmission of the death signal to the caspase cascade
allowing the survival of the mutated cell. In this chapter, a mathematical model that
explores the effect of Mdm2 overexpression and the suppression of caspase-9 on the
control of death by the p53–Mdm2 loop is presented. From the model, two strategies
for tumor cell survival are indentified, showing how mutations that affect the death
pathway allow the survival of transformed cells. The model suggests that the
combination of different simultaneous treatments against these mutations can be a
suitable strategy against cancer.
Keywords: Cancer, p53–Mdm2 feedback loop, Mdm2 overexpression, suppression
of caspase-9 gene
1. Introduction
Cancer has become one of the most important chronic diseases around the world [1]. A great
number of studies on cancer have been focused on the identification for the genetic factors
responsible of the predisposition for it. All these works have reported that a wide range of
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genes is implicated, as well as a great number of environmental factors that increase cancer
risk [1]. From a dynamical point of view, cancer is a complex robust system, in which many
of the feedback motives that assure the homeostasis of cells have been altered, allowing a
perturbed state of the cell in which it growths and proliferates at an increased rate.
The complexity of cancer lies on the high number of punctual DNA mutations (~105 per cell),
which are grouped in a small number of signaling circuits, which seems to be the same
recurring pathways [2]. In malignant tumors, mutations comprise oncogenes and tumor
suppression genes like Mdm2, which takes part in the negative p53–Mdm2 feedback loop that
controls the entrance of the cell to apoptosis [3]. Mdm2 is an E3 ubiquitin ligase that maintains
low p53 levels in normal cells. However, under stress of genotoxic signals, Mdm2 inhibition
on p53 is released, and several different responses are activated, including cell arrest and
apoptosis.
The importance of the p53–Mdm2 loop in the tumor suppression is reflected in the fact that
almost 50% of malignant tumors present a mutation in the p53 gene [4]. In cells without p53
mutation, the tumor suppression function of the p53 transcription factor can be stopped by
overexpression of Mdm2, blocking the entrance of the cell to apoptosis. Another mechanism
to override p53 tumor suppression function is the uncoupling of the caspase cascade from the
intrinsic apoptosis pathway; mutations in caspase-3 and caspase-9 can be responsible for this
uncoupling.
This chapter explores the dynamics of the p53 tumor suppression system under normal and
stress conditions in order to understand how overexpression of Mdm2, and mutations in the
components of the caspases cascade, alters the form in which p53 controls the entrance of the
cell to apoptosis. The dynamic features of the ordinary and altered operation conditions of
p53–Mdm2 feedback loop are explored with a mathematical model that links it with the
caspase cascade. The biological implications of the results obtained from the model are
discussed in deep to understand how the deregulation of the intrinsic apoptotic pathway leads
the modified cells to escape from death.
2. Molecular biology of the p53 pathway
2.1. The p53 pathway
Activation of the p53 pathway starts under the command of a complex feed forward structure
implied in DNA damage detection, which is formed by proteins like the histone acetyl
transferase Tip60 and the MRN complex. These proteins induce the activation of the ATM
kinase [5–7]. In the next step, ATM phosphorylates and activates histone H2AX and other
proteins with a BRCT domain (such as Nbs1, 53BP1, and MDC1) [7, 8]. These proteins will
bind to the broken segment of DNA in order to stop the spread of damage [8]. Similarly, ATM
activates Chk2 kinase, partially responsible for promoting cell cycle arrest [8, 9]. Chk2 also
promotes the activity of the transcription factor E2F-1 [9], which regulates the expression of
Chk2 and proapoptotic proteins ASPP [10] (Figure 1).
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The active nuclear form of ATM assembles a complex with NEMO, which is ubiquitinated and
transported to the cytoplasm where induces the release of the transcription factor NF-ĸB [11],
a factor that enters the nucleus and promotes the expression of various genes [12, 13], including
BCL-XL [14, 15]. Simultaneously, in the nucleus, active ATM phosphorylates the p53 store,
and Mdm2 becomes less effective to recognize p53 delaying its degradation. In addition, ATM
phosphorylates Mdm2 and induces its self-ubiquitination and degradation in the proteosome,
allowing the increase of p53 nuclear concentration over time [16].
On the other hand, active Chk2 phosphorylates p53 to stabilize its structure [8]. At the end of
this initial cascade of phosphorylation, p53 can interact either with accessory proteins ASPP1,
ASPP2, or with MUC1 [17, 18] (Figure 1). In response to genotoxic stimuli, the transmembrane
glycoprotein Musin-1 (MUC1) is cleaved, and the cytoplasmic segment is targeted to the
nucleus, allowing it to bind to phosphorylated p53, inducing cell cycle arrest [19–24]. However,
if there is severe DNA damage, p53 binds mainly to ASPP proteins, enhancing the proapoptotic
function of p53 [25]. Thus, according to the intensity of the stimulus, p53 can be oriented either
to transcribe proapoptotic genes or antiapoptotic genes, depending on the accessory proteins
to which it is attached.
When the DNA damage signal is weak, nuclear concentration of MUC1 increases and enhances
its binding to p53. After that, p53/MUC1 interacts with p300/CBP-associated factor (PCAF) to
form a new complex [18, 26]. PCAF acetylates p53 on lysine 320, allowing it to recognize
specifically the promoters of genes related with DNA damage repair and cell cycle arrest, as
p21WAF1/cip1 [18]. MUC1 blocks Bax dimerization and the Bax-mediated release of cyto‐
chrome c [27]. MUC1 is capable of enhancing the expression of ARF, resulting in Mdm2
repression [28]. When p53/MUC1 complex starts its nuclear functions, the deacetylase SIRT1
opposes the PCAF-dependent acetylation of p53 by removing the acetyl group, blocking its
transcriptional activity when the cell does not have enough energy to express proteins [29–31].
However, SIRT1 is not the only control point of p53. As it was discussed above, active ATM,
along with NEMO, turns on NF-ĸB, which promotes the expression of antiapoptotic genes like
BCL-XL [15].
NF-ĸB competes with p53 for the cofactors acetyltransferases p300, CBP, and PCAF, which are
required for the binding of p53 to DNA [32, 33]. The effect of such interaction leads to the
indirect repression of the transcriptional activity of p53 because the concentration of the
cofactors remains relatively constant [11, 32, 34] (Figure 1).
Once nuclear p53 is activated, it starts the transcription of sensor genes like the phosphatase
Wip1 and Mdm2 (in its p90 isoform) in order to activate the negative feedback control of the
pathway. Wip1 function is to dephosphorylate Chk2, ATM, activated p53, and phosphorylated
Mdm2. This action leads to inactivation of all of these proteins, except Mdm2 that is activated
[25, 33, 35–38]. The dephosphorylated form of Mdm2, together with activated Wip1 and new
synthesized Mdm2, inhibits p53 and reduces its nuclear concentration, avoiding its transcrip‐
tional activity [39]. Because of Wip1 function, the signal generated by ATM and Chk2 blinks
while DNA damage is not repaired since ATM activator proteins remain linked to broken DNA
[33, 40, 41]. When DNA damage is repaired, the nuclear topology is restored and ATM
activating proteins stops the signal. In this case, Wip1 definitely inactivates ATM and its
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effector molecules like Chk2. This encourages Mdm2 (p90 isoform) to suppress efficiently p53
activity, allowing the cell to return to its normal state. The levels of p90Mdm2 and Wip1 also
return to their basal value [38] (Figure 1). If the signal of DNA damage is either too strong or
persistent, and the cell has not enough energy to repair the damage, p53 binds to ASPP proteins
and forms a complex with the histone acetyltransferase p300/CBP to acetylate p53 on lysine
373 [26, 42].
Another regulatory interaction is held by proteins p90 and Tip60. The interaction of p90 with
p53 allows Tip60 to transfer an acetyl group to Lysine 120 of p53 [43]. Together, these chemical
modifications permit the selective recognition of the promoter sites of proapoptotic genes like
PUMA, Bak, and Bax by p53 [43, 44]. It is noteworthy that the formation of the p53/p300
complex is reversible, and p300 is separated from the complex by the deacetylation of p53 [30].
The enzyme responsible for this step is the deacetylase SIRT1 [30, 45]. This enzyme uses NAD
+, from the cellular metabolism, as a cofactor; typically, SIRT1 activity can delay the apoptotic
intrinsic pathway when there is no sufficient metabolic energy and whether DNA damage is
not enough to activate apoptosis directly; nonetheless, this enzymatic regulation has no
importance when DNA damage is severe [30].
In the cytoplasm, p53 forms a complex with the antiapoptotic protein BCL-XL in order to create
a cytoplasmic reserve of p53 [16, 46]; in parallel to this, the excess of free BAX is neutralized
in the cytoplasm by forming a complex with the antiapoptotic protein BCL2 [3]. Once the cell
has chosen to die, p53 enhances the expression of proapoptotic genes like Bax, PUMA, NOXA,
Figure 1. The p53 pathway.
Evolution of Ionizing Radiation Research6
BID, p53AIP, DR5, caspase-6, PERP, and FAS [47]. As a result, PUMA cytosolic concentration
increases and enables its interaction with the p53/BCL-XL complex, replacing p53; in turn, free
cytoplasmic p53 interacts with complex BCL2/BAX in order to form a new complex BCL2/p53,
releasing BAX into the cytoplasm [46–48]. Free BAX monomers will interact with other Bak
and Bax monomers to form the mitochondrial apoptosis-induced channel (MAC), and those
complexes will perforate mitochondrial outer membrane, allowing the release of cytochrome
c, SMAC/DIABLO, and Omi/HTRA [47, 49], triggering the commitment step in the apoptotic
intrinsic pathway. Free cytochrome c will interact with apoptotic protease activating factor 1
(Apaf-1) and procaspase-9 to form the apoptosome. At the same time, cytosolic SMACs block
the repression of inhibitor of apoptosis proteins (IAPs) on the initiator and executer caspases,
ensuring apoptosis effectiveness [50–57]. Then the apoptosome cleaves the inactive procas‐
pase-9 to active initiator caspase-9, and then it will activate executer caspase-3 [58]. Once this
protein is activated, it starts a positive feedback loop for its self-activation as well for the
activation of initiator caspases [59]. Caspase-3 starts the degradation of the cytoskeleton and
other important cellular components, triggering the exposure of phosphotidylserine on the
outer leaflet of the apoptotic cells, allowing the noninflammatory phagocytic recognition of
these cells [47, 60] (Figure 1).
3. Nonlinear dynamics
3.1. Cells are complex networks
Cells are formed by several types of molecules (nodes) that are linked by the interactions
between them forming a complex and hierarchical network. This network consists of a series
of subnetworks that controls cellular processes like signaling, metabolism, apoptosis, tran‐
scription, translation, and DNA repairing and modification. The links between nodes can be
of several types, including protein–protein, protein–DNA (transcription factors), small
molecule–DNA (acetylation, methylation, etc.), small molecule–protein (posttranslation
modifications), and metabolic [12]. Furthermore, these interactions are organized in clusters,
with specific motives such as feedforward structures, single-input modules, or feedback
modules [12]. This modular architecture of the cell’s network is regulated by global regulators
or “hubs” such as p53, mTOR, or AMPK [61].
3.2. The control principles of biology
A remarkable property of the cellular network is that all of its connections respond to specific
and well-defined stimuli; in other words, such interactions are controllable. In this form, the
modular structure of cells allows them to control several processes simultaneously, depending
of the received inputs. Control is exerted by specific regulatory structures or motives like the
negative feedback loop.
In order to understand why the negative feedback loop is so important for the control of the
cellular processes, the block diagram of Figure 2A shows the functioning of this motive when
a reference signal (or input) r is transformed into an output signal y. From this diagram,
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y rG rG yG yGd= + D + - - D (1)
where G corresponds to a system, Δ is the intrinsic noise proper of the system, and G and δ is
the extrinsic noise due to external factors.
Working Equation (1) algebraically, we obtain
( )
( ) ( )
rGy G G
1
1 1 1 1
d+ D= +
+ + D + + D (2)
That is equivalent to
( ) ( )
ry G G1 1 1 1 1
d= ++ D + + + D (3)
According to Equation (3), if the regulation of the system G tends to be stronger (i.e., G →∞),
then the input signal will be totally transformed into the output, regardless the presence of
intrinsic and extrinsic noise. In other words,
y r= (4)
In this form, negative feedback loops are able to neutralize interferences due to extrinsic and
intrinsic noise. This characteristic is known as robustness, and it confers to the system the
capability to function in a changing environment like the intracellular medium [62, 63], which
explains why negative feedback motives are so common in cell biology. In regard to robustness,
it was thought that redundancy was its obligated synonym because if the cell loses a determined
connection, and there are redundant interactions, then the cell can compensate the absence of
such a connection. However, one system can be redundant but not robust depending on the
type of connections that are redundant. At the molecular level, redundant interactions
contribute to enhance the regulation of a biological process, which is a sine qua non condition
to reject all effects of intrinsic and extrinsic noises [62].
Besides redundant connections, the cell also has contradictory interactions in which a biolog‐
ical molecule simultaneously activates and represses one process. These motives are better
known as feedforward loops, and sometimes they are called incoherent feedforward motives
[64]. In order to understand why the cell needs to activate and to repress one process at the
same time, from Figure 2B, the block diagram can be written as follows:
y rCAP rC rAP r yCAP yC d= - - D + + D + + D + (5)
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where P is the process to be controlled (e.g., transcription or translation), A is the molecule that
physically modifies and executes the process (e.g., RNA polymerase), and C is a biological
controller unit (e.g., a signaling circuit).
Working this algebraic expression, we obtain
( )
( )
( )
( ) ( )
rC AP r APy C AP C AP C AP1 1 1
d- + D + D= + +- + D - + D - + D (6)
That is equivalent to
( )( )
( )
( ) ( )
r APry C AP C APC AP 1 1 11
d
-
+ D-= + +- + D - + D+ D - (7)
Once again, if the control of the system (Equation 7) tends to be stronger (i.e., C →∞), then we
obtain Equation (4), which means that this structure also neutralizes the effects of intrinsic and
extrinsic noises. Thus, this apparently incoherent motive has robustness as well as negative
feedback loops. Nevertheless, in order to exert their full robustness properties, these motives
must be faster than the negative feedback ones during the regulation of a process, and their
robustness is given by the fact that they can prevent a disturbance before it occurs [65]. For
such reasons, feedforward motives are useful to control complex systems like positive
feedback loops or nonlinear processes like splicing.
However, none of these cellular motives could be effective without biological controllers.
In fact,  such devices are specifically designed for operating a determined control motive
such  as  negative  feedback  loops,  feedforward  loops,  or  open  loops  (i.e.,  without  feed‐
back, Figure 2C) [66].
However, there is a general structure for assembling controllers (Figure 3A), which consists in
coupling a comparator and a control action module (the core of controller) with an amplifier
[66]. The comparator is a device that collects and contrasts the reference signal (input) with
the signals produced by either a sensor (device that measures the output of the system) or a
timer (in open-loop systems). The difference between these signals is known as the error signal
(e(t)), and it is used by the core of the controller to activate its inner mechanism in order to
produce a control signal. Then the amplifier augments the potency of the control signal for
regulating the entire system [66].
There are many types of controller cores, but the simplest are on–off cores (all or nothing
control). Mathematically, this controller core is described by the following equation:
( ) ( )( )
e tu t e t
1,
0,
a
a
³= <
ìïíïî
(8)
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It means that the controller core will produce a control signal only if the magnitude of error
signal is higher than a threshold value (α) [66]. In turn, this signal will be interpreted by the
system as an order for turning on its functioning.
However, if the error signal magnitude is below the threshold value, the controller core will
turn off the system. It is important to remark that such controller cores could be problematic
when the error signal has an irregular behavior as shown in Figure 3B. To deal with that error
signals, there is a special variant of on–off cores that includes a memory range (Figure 3C).
This type of core is known as on–off with hysteresis [66] and generically is described by the
following equation:
( ) ( )( )
e tu t e t
1,
0,
a
a
³= < -
ìïíïî
(9)
Figure 2. Control motives. (A) Negative feedback loops with the presence of intrinsic (Δ) and extrinsic noises (δ). (B)
Feedforward motives with intrinsic and extrinsic noises. (C) Open-loop motives. In all cases, C is the controller, A is
the effector, P is the plant or process to be controlled, and G represents the whole system.
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It means that the core will produce a control signal only when the magnitude of the error signal
is higher than a threshold value (α), and it will stop when the error signal is below another
threshold value (- α). With this modification, the controller core does not change unexpectedly
because of fluctuations in the error signal [66]. In cell biology, we can find this controller core
almost everywhere. For example, in molecular switches (Figure 3D) at transcriptional level,
one gene cannot be fully transcribed unless there is enough concentration of its inducer [63, 67].
Figure 3. Biological controllers. (A) The canonical structure of a controller. (B) Temporal response of a core controller
all or nothing. (C) Temporal response of a core controller all or nothing with hysteresis. (D) Biological equivalence to a
core controller all or nothing with hysteresis.
Dynamics of p53 and Cancer
http://dx.doi.org/10.5772/60916
11
3.3. Control principles on the p53 pathway
An example of control principles applied to biology can be observed during the evaluation of
the DNA damage (Figure 1). This process is performed by some specialized kinases such as
ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR), as well
as some DNA binding proteins like the MRN complex (Mre11, Rad50, and Nbs1) [8]. If these
proteins do not detect any DNA damage, the cell cycle will continue normally [68]. But if so,
they will activate a feedforward signaling structure in order to induce the cell cycle arrest
through effector molecules such as Chk2 and p21Waf1/cip1 [69]. Furthermore, when DNA
damage is severe, the cell will turn on apoptosis through p53 transcriptional activity [68].
The p53 transcription factor also regulates the expression of genes responsible for the cell cycle
arrest, repair of DNA damage, senescence, apoptosis, and other signaling pathways [70, 71].
The expression of p53 gene is activated by many inputs from transcriptional factors that
include the p50 subunit of NF-ĸB, C/EPEβ-2, Ets-1, Pitx1, p73, and p53 itself [72–75]. Cyto‐
plasmic p53 concentration is regulated in a negative feedback motive that starts when a fraction
of p53 interacts with the anti apoptotic protein BCL-XL to generate a heterodimer [46, 76], and
the remaining fraction of p53 is marked in its carboxyl-terminus with a nuclear import signal
(NLS1) to be subsequently transported into the nucleus, where it interacts with its natural
repressor: the ubiquitin ligase Mdm2 (Hdm2 in humans).
On the other hand, the negative regulator Mdm2 is an example of a biological sensor because
its expression is a consequence of the p53 transcriptional activity, which allows the formation
of a negative feedback loop. However, many studies suggest that p53–Mdm2 interactions are
more complicated than it was thought; mainly because the Mdm2 gene has two promoters (P1
and P2) that can generate at least two isoforms of Mdm2 [35]. The first one isoform (p90Mdm2)
is responsible of the p53 inhibition, but the second one (p76Mdm2) promotes the translation
of p53 mRNA [35, 77]. Under ordinary conditions, p76Mdm2 expression is greater than
p90Mdm2 [78], generating basal levels of p53 throughout the cell cycle. However, under
cellular stress conditions, p53 induces the expression of p90Mdm2 in detriment of the
p76Mdm2 isoform [77]. Remarkably, it was reported that other transcriptional factors can
activate the Mdm2 gene in order to increase the regulation of p53, which is a clear example of
the enhancement of biological robustness due to redundant interactions [78].
3.4. Nonlinear dynamical systems
All previous concepts are useful for understanding how the cell coordinates its molecular
processes. However, it is important to introduce some concepts from dynamical systems prior
to analyze how cells make operative decisions.
Most of the cellular processes can be represented in mathematical terms with nonlinear
differential equations, which together with a set of initial conditions define a dynamical
system. In this form, if the state of a system at time t is determined by the set of variables
{x1(t), x2(t), ..., xn(t)}, then the respective dynamical system is the set of nonlinear differential
equations xj(t)= f j(x1(t), x2(t), ..., xj(t), ..., xn(t)),  j =1, 2, ..., n, subject to the initial conditions
{x1o(0), x2o(0), ..., xno(0)}. The set of variables {x1(t), x2(t), ..., xn(t)} defines the phase space of the
Evolution of Ionizing Radiation Research12
dynamical system in which the motion of the system occurs. As time goes on, the point
x(t)= x1(t), x2(t), ..., xn(t)  moves along the phase space and defines a curve o trajectory of the
system for each initial condition. Thus, the objective is to analyze the dynamical system in
order to know the complete set of trajectories of the system in the phase plane (the phase
portrait), and to discern the behavior of the trajectories in the neighborhood of the equilibrium
o fixed points of the dynamical system. Equilibrium or fixed points are the points of the phase
plane in which all the derivates vanish. As an example, in Figure 4, the phase portrait of the
two-dimensional dynamical system x˙ =sin(y), y˙ = x − x 3 is shown:
Figure 4. Portrait phase of the system x˙ =sin(y), y˙ = x − x 3.
Nonlinear dynamical systems cannot be analytically solved; however, there are mathematical
tools that can be used to know the qualitative behavior of the system. One of these tools is the
linearization around a fixed point.
Let xo = (x1o, x2o) be a fixed point of the two-dimensional dynamical system:
( )
( )
x f x x
x f x x
1 1 1 2
2 2 1 2
,
,
=
=
&
& (10)
If fluctuations δx1 and δx2 perturb the fixed point xo, the system is displaced to a new state
δxo = (x1o + δx1, x2o + δx2), and the trajectory that emerges from this point of the phase plane can
either bring closer to the original equilibrium or go far away from it. If the trajectory tends to
the fixed point in an asymptotic form, then xo is stable, and it is an attractor. If the trajectory
moves away from the fixed point, then xo is unstable, and it is a repeller.
The dynamical behavior of the fluctuations determines the stability of the system, and it is
essential to establish a form to analyze the evolution of the fluctuation along time. In order to
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achieve this goal, it is necessary to assume that the behavior of the fluctuations in the neigh‐
borhood of the fixed point is linear, i.e., the nonlinear terms can be neglected.
From Equation (10),
( ) ( )
( ) ( )
( )
( ) ( )
( ) ( )
( )
o o o o
o o o o
o o o o
x x x x
o o o o
x x x x
f ff x x x x f x x x x O x x x xx x
f ff x x x x f x x x x O x x x xx x
1 2 1 2
1 2 1 2
2 21 1
1 1 1 2 2 1 1 2 1 2 1 2 1 2
1 2, ,
2 22 2
2 1 1 2 2 2 1 2 1 2 1 2 1 2
1 2, ,
, , , ,
, , , ,
d d d d d d d d
d d d d d d d d
¶ ¶+ + » + + +
¶ ¶
¶ ¶+ + » + + +
¶ ¶
(11)
Neglecting the nonlinear terms and taking into a consideration that the derivates vanish in the
fixed point, Equation (11) can be written as
( ) ( )
( ) ( )
o o o o
o o o o
x x x x
x x x x
f fx x xx x
f fx x xx x
1 2 1 2
1 2 1 2
1 1
1 2
1 2, ,
2 2
1 2
1 2, ,
1
2
d d d
d d d
¶ ¶+
¶ ¶
¶ ¶+
¶ ¶
=
=
&
&
(12)
which can be written in a matrix form as
( )o ox x
x x
x x
f f
x x
f f
x x
1
2
,1 2
1 1
1 21
2 2 2
1 2
d d
d d
¶ ¶
¶ ¶= ¶ ¶
¶ ¶
é ùê úé ù é ùê úê ú ê úê úë û ë ûê úë û
&
& (13)
Equation (13) represents the dynamics of the fluctuations around the fixed point when the
nonlinear terms are neglected. The stability of the fixed point is then determined by the matrix
J(xo)=
∂ f 1
∂ x1
∂ f 1
∂ x2
∂ f 2
∂ x1
∂ f 2
∂ x2 xo
, which is the Jacobian of the dynamical system. In two-dimensional dynam‐
ical systems, the evolution of the trajectories in the phase plane is settled on by the roots of the
characteristic equation of the Jacobian: λ 2 + tr(J)λ + det(J)=0, where tr(J) is the trace of the matrix
and det(J) its determinant. This characteristic equation has two roots, known as eigenvalues,
that can be real, imaginary, or complex numbers. In all cases, if both λs are negative real
numbers or complex numbers with a negative real part, the fixed point is stable, and it is an
attractor. If at least one of the roots is a positive real number or has a positive real part, the
system is unstable. Figure 5 summarizes the properties of eigenvalues for any system. In the
general case of an n-dimensional dynamical system, there are n eigenvalues, and if all of them
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are negative real numbers or are complex numbers with negative real part, the fixed point is
an attractor. Otherwise, if a least one eigenvalue is a positive real number or a complex number
with a positive real part, the fixed point is unstable.
Figure 5. Portrait phases for different eigenvalues. (A) The portrait phase of one system is described by a stable node
(sink) when Re(λi) < 0, i = 1,2, and there is no imaginary part. (B) On the other hand, if Re(λi) > 0, i = 1, 2, the portrait
phase will show an unstable node (source). (C) Similarly, when Re(λi) < 0, i = 1, 2, and there is an imaginary part, the
system presents a stable spiral (sink). (D) In case of Re(λi) > 0, i = 1, 2, and if there is an imaginary part, the system will
present an unstable spiral (source). (E) When Re(λi) = 0, i = 1, 2, and there is an imaginary part, the portrait phase of the
system will show a center (it is stable, but not asymptotically stable like a sink). (F) If the system has real eigenvalues
with different signs, for instance, λ1 > 0 and λ2 < 0, the system will present a saddle point. In all cases, the origin is the
equilibrium and is marked with a black cross, and the arrows show the direction of trajectories.
If Re(λ1,2) ≠ 0, the fixed points are hyperbolic points, which are robust points that cannot be
altered by the small nonlinear terms. Fixed points like stable nodes and stable spirals are
hyperbolic points. The Hartman–Grobman theorem affirms that the phase portrait in the
neighborhood of a hyperbolic fixed point of a nonlinear system is topologically equivalent to
the phase portrait of the linearization, i.e., the phase portrait of the nonlinear system is an
invertible deformation of the phase portrait of the linearized system. A phase portrait whose
topology cannot be altered by small nonlinear perturbations is structurally stable.
The phase portrait of a dynamical system can be modified as some parameter of the system
varies, giving rise to qualitative changes in its structure. Such dynamical transitions are known
as bifurcations. They generally occur in a one-dimensional subspace, and the remaining
dimensions of the phase plane are affected as a consequence of the trajectories that can be
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attracted or repelled from this subspace. Bifurcations can lead to the rich qualitative behavior
characteristic of nonlinear systems that includes bistability, biological switches, circadian
rhythms, bursting, and traveling waves, among others.
Considering the imaginary plane, we can roughly classify bifurcations into two cases: (1) the
eigenvalues of the Jacobian matrix are both real and bifurcations occur along the real axis as
certain parameter changes. This kind of bifurcation comprises the saddle-node bifurcation, the
transcritical bifurcation, and subcritical and supercritical pitchfork bifurcation. (2) The
eigenvalues of the Jacobian matrix are complex conjugated. Bifurcations occur crossing the
imaginary axis as certain parameter changes. This kind of bifurcation comprises the super‐
critical and subcritical Hopf bifurcation.
The formation of the complex by fibroblast growth factor (FGF) and its receptor and the
subsequent homodimerization of the complexes can be taken as an example of a dynamical
system. The biochemical reaction is
( ) ( )
k
k
k
k
1
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2
2
FGF FGFR FGF FGFR
2 FGF FGFR FGF FGFR 2
-
-
+ -
- -
¾¾®¬¾¾
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The corresponding dynamical system is
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-
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(15)
where FGFT is the total amount of the agonist in the medium, FGFRT is the total amount of FGF
receptor in the cell’s membrane, c is the amount of the complex agonist–receptor FGF-FGFR,
c2 is the amount of the homodimer complex (FGF-FGFR)2, and k1, k–1, k2, and k–2 are the rate
constants. For the following particular values of parameters and constants, FGFT = 1 µM,
FGFRT = 0.5 µM, k1 = 1 µM–1s–1, k–-1 = 0.004 s–1, k2 = 2 µM–1s–1, and k–2 = 1.8 s–1; the fixed points are
A(0.4652, 0.24) and B(1.0747, 1.282). The linearized system is
c cc
c cc2 2
2 1.54 0
4 1.8
d d
d d
-= -
é ù é ùé ùê ú ê úê úë ûë û ë û
&
& (16)
and the Jacobian of the linearized system is
( )
o
o c
c
2 1.54 0
4 1.8
-= -
é ùê úë û x
J x (17)
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Figure 6. Portrait phase of the FGF model.
Evaluating the Jacobian (Equation 17) in each fixed point, the eigenvalues for the fixed point
A are both real negative, and for the case of point B, one eigenvalue is real negative while the
other is real positive. Thus, the fixed point A is a stable node, while the fixed point B is a saddle
point. In Figure 6, the phase portrait of the dynamical system is shown, in which the saddle
point is an energetic barrier that separates the dynamics of the system around the node from
the dynamics of the outer region of the phase space, which is filled of trajectories that contin‐
ually diverge. Both fixed points are hyperbolic and the phase portrait is structurally stable.
4. Modeling apoptosis
4.1. Mathematical modeling of the p53 pathway
p53 has a central role in the control of apoptosis and in the induction of death in cells after
chemotherapy or radiotherapy. One of the main characteristics of the control of apoptosis by
p53 is the existence of oscillations in the p53–Mdm2 negative feedback loop whose frequency
and duration determine the entrance of the cell to apoptosis. These oscillations arise through
a supercritical Hopf bifurcation in response to DNA damage signals [37, 79].
Many attempts have been done to understand how the negative p53–Mdm2 feedback loop
sustains the observed p53–Mdm2 oscillations. These models have addressed that oscillations
can arise in systems in which there is a sustained input signal and a single negative feedback
loop with a delay term. However, models of this type are unable to produce multiple oscilla‐
tions and are necessary to introduce a positive feedback in the core of equations to reproduce
a wide range of oscillatory responses experimentally observed [80]. Nevertheless, the dynam‐
ical features of this kind of models are not robust against changes in the value of the parameters,
and new attempts have been done to correct this problem by introducing additional feedback
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motives in the model that improve robustness but cannot explain the observed variability in
the p53 and Mdm2 oscillations in cell populations [81]. Stochastic models have been proposed
in order to overcome these limitations of deterministic models. In this kind of modeling,
random variables like noise or DNA damage are taken into consideration in the core of the
equations giving rise to a series of oscillations with variable amplitude in concordance with
the experimental observations [80].
Figure 7. Minimal model of the p53 pathway.
Proctor and Douglas [81] proposed two stochastic mechanistic models of the p53–Mdm2
feedback loop. The first model explores the inhibitory effect of p14ARF on Mdm2, which leads
to the stabilization of p53; the second model explores the effect of the phosphorylation of both
Mmd2 and p53 by ATM. From both models, oscillations p53 and Mdm2 with high variability
are obtained; however, the ATM model exhibits more variability. Both models are robust for
a wide range of parameter values, indicating that stochasticity could be a basic component of
the cell’s response to DNA severe damage. Liu et al. [82] proposed a complete stochastic model
of p53 and apoptosis with three-coupled modules. The first module represents the p53–Mdm2
feedback loop dynamics; the second module represents cytochrome c release from the
mitochondria, and the third module represents caspase activation. Results from this model
indicate that the major determinants of cell fate are the strength of p53 transcriptional activity
together with its coupling to mitochondrial opening. This model indicates that p53 oscillations
are a necessary but not sufficient condition for the onset of apoptosis. In this point, the Bax
molecules located at the surface of the outer mitochondrial membrane have a central role in
driving apoptosis, indicating that the possible role of the p53–Mdm2 system is to control the
cytoplasmic levels of activated Bax.
Bistability is a broad dynamical feature of nonlinear biochemical systems, in which a saddle-
point separates two stable nodes. The transition between nodes requires energy to overcome
the high energetic barrier between them, leading to a saddle-node bifurcation. Generally, once
the transition from one steady point to the other occurs, return to the original state needs a
different pathway with different energy requirements, forming a hysteresis loop. Molecular
switches are the common examples of this type of dynamics [83].
Bagci et al. [60] studied the role of Bax, Bcl2 synthesis, and degradation rates in mitochondria-
dependent apoptosis, finding the existence of a saddle-node bifurcation in the caspase-3-Bax
degradation rate diagram. This bifurcation drives the system either to a stable point with a
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high concentration of caspase-3 (cell death) or to a stable point with a low concentration of
caspase-3 (cell survival). Out of this region, the systems dynamics is settled on by the existence
of a single stable fix point that determines cell surviving independently of the concentration
of caspase-3. An important conclusion from this work is that an abnormal state, like cancer,
arises in cells when Bax degradation rate is above a threshold value, giving rise to a stable cell
survival dynamics, i.e., cells do not die.
In order to explore the dynamics of the caspase cascade when coupled to the p53 pathway by
Bax switch, a model of ordinary differential equations (ODEs) is proposed (Figure 7). However,
this model takes into account only the most representative nodes of the pathway (Section 2.1):
p53, Mdm2 and its mRNA, Bax, IAPs, active initiator caspase-9, and the active executioner
caspase-3 (Figure 7B). Besides its simplicity, this model reproduces the oscillatory dynamics
of the p53–Mdm2 and its effects on the activation of caspase-3. In this model of the p53
pathway, the concentration of p53 is given by
[ ] [ ] [ ][ ] [ ]kt act 1 1
d p53 p53 p53 Mdm2 p53d a d= + - (18)
where α act is the rate of p53 synthesis, k1 is the affinity of Mdm2 to p53, and δ 1 is the p53 rate
of decay. In a similar form, the concentration of the Mdm2 mRNA is given by
[ ] [ ] [ ]t 1 2
d mRNA p53 mRNAd a d= - (19)
where α 1 is the rate of mRNA synthesis due to p53 activity and δ 2 is the mRNA rate of decay.
Continuing with the model, the concentration of Mdm2 is given by the following equation:
[ ] [ ] [ ][ ] [ ]kt 2 1 3
d Mdm2 mRNA p53 Mdm2 Mdm2d a d= + - (20)
In this equation, α 2 is the rate of Mdm2 synthesis, and δ 3 is the Mdm2 rate of decay. The next
equation represents the fraction of free Bax protein:
[ ] [ ] [ ]( )[ ] [ ]TB k B B Bt 2 4
d * * p53 *d d= - - (21)
where k2 is the rate of Bax release due to p53 activity, [B*]T is the total concentration of Bax
protein and δ 4 is its rate of decay. The following equation represents the decrease of IAPs
activity due to free Bax:
[ ] [ ][ ]I k B It 3
d *d = - (22)
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Finally, we have the equation for the activation of initiator caspase-9:
[ ] [ ] [ ]( ) [ ] [ ]( ) [ ]( )[ ]C k C C B C k I Ct 4 5 5T
d 9* 9 9* * 3* 9*d d= - + - + (23)
Moreover, the equation for the activation of executioner caspase-3 is as follows:
[ ] [ ] [ ]( ) [ ] [ ]( ) [ ]( )[ ]C k C C C C k I Ct 6 6 5T
d 3* 3 3* 9* 3* 3*d d= - + - + (24)
where k4 and k6 are the rates of activation, δ 5 and δ 6 are the rates of caspases decay, and k5 is
the rate of repression due to IAPs activity. All parameters of the model are reported in Table
1. The initial concentrations (µM) of the variables are
[ ] [ ] [ ] [ ] [ ] [ ] [ ]I B C C0 0 0 0 0 0 0p53 0.01 1 mRNA Mdm2 * 9 * 3 * 0= = = = = = =
Parameter Value Biological meaning
α act 0.15 s–1 Low damage
0.2 s–1 Medium damage
0.3 s–1 Strong damage
Rate of p53 synthesis
k1 1 µM–1 s–1 Rate of p53 degradation due to Mdm2 repression
δ1 0.01 s–1 Basal degradation of p53
α 1 1 s–1 Rate of Mdm2 RNA synthesis due to p53
δ 2 0.1 s–1 Basal degradation of Mdm2 RNA
α 2 0.1 s–1 Rate of synthesis of Mdm2
δ 3 0.5 s–1 Basal degradation of Mdm2
k2 0.1 µM–1 s–1 Rate of Bax releasing due to p53 activity
δ 3 0.1 s–1 Basal degradation of Bax
k3 0.02 s–1 IAPs inhibition due to Bax activity
k4 0.01 µM–1 s–1 Rate of procaspase-9 activation
δ 5 0.1 s–1 Basal degradation of caspase-9
k5 10 µM–1s–1 Inhibition of caspase-9 due to IAPs activity
k6 0.1 µM–1s–1 Rate of procaspase-3 activation
δ 6 0.1 s–1 Basal degradation of caspase-3
[B]T 1 µM Total concentration of Bax
[C9]T 1 µM Total concentration of caspase-9
[C3]T 1 µM Total concentration of caspase-3
Note: all parameters were estimated for this work.
Table 1. Model parameters
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4.2. Dynamical features of the p53 pathway
From the above model, it is possible to visualize the main molecular events in the p53 pathway,
as well as the activation of apoptosis. In the model, soft damage in DNA is interpreted as an
increase of p53 synthesis. In this scenario, the p53 concentration presents damped oscillations
(Figure 8A), which are represented by a stable spiral in the p53-Mdm3 phase plane (Figure
8B). With this level of DNA damage, the system does not activate apoptosis because the
caspases-3 concentration remains zero (Figure 8C). When DNA damage reaches a medium
level, the p53 concentration exhibits more pronounced damped oscillations, i.e., the stable
spiral has a higher initial amplitude and a larger relaxation time (Figure 8D). However, if the
DNA damage persists for long time, the active caspase-3 concentration will augment until it
starts apoptosis irreversibly (Figure 8F). Moreover, when DNA damage is severe, the p53
Figure 8. Dynamics of a simplistic model of p53 pathway and apoptosis. When the cell receives a soft damage on
DNA, a few damped oscillations on p53 concentration (A) appear, which correspond to a stable spiral (B), and there is
no increase in active caspase-3 concentration (C). When the damage on DNA is stronger, p53 exhibits stronger damped
oscillations (D), and after a certain time, apoptosis starts (F). Finally, when DNA damage is severe, p53 oscillations are
not damped (G), and a limit cycle is settled on (H), leading to a faster start of apoptosis (I). For all simulations, the time
scale is in minutes, and concentrations are in micromolar units.
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pathway undergoes a supercrital Hopf bifurcation (reviewed in [83]), which means that the
stable spiral (Figure 8E) becomes a stable limit cycle through an unstable spiral (Figure 8G).
During the bifurcation process, the caspase-3 activation is faster, which implies that the cell
has no option but to die (Figure 8I). Thus, p53 concentration acts as a biological timer and
allows the cell to response in a specific way for certain perturbations, such as DNA damage
intensity and duration. In addition, the activation of caspase-3 is governed by a control action
of an “all or nothing” scheme, which avoids the random activation of apoptosis.
4.3. Over expression of Mdm2
In the nature, there are many factors that can permanently perturb the p53 network function‐
ing, such as genetic alterations like deletions or constitutive overexpression due to polymor‐
phisms [84]. A classical example of this point is the overexpression of Mdm2, which is present
in more than forty different types of cancer, taking a central role in cancer development [85].
In order to know how the overexpression of Mdm2 perturbs apoptosis, Equation (20) of the
model (see Section 5.1) can be modified as follows:
[ ] [ ] [ ][ ] [ ]kt 2 onco 1 3
d Mdm2 mRNA p53 Mdm2 Mdm2d a e d= + + - (25)
where ε onco is a parameter and represents the external factors that induce the Mdm2 overex‐
pression.
From a dynamical point of view and according to the model results, Mdm2 overexpression
disrupts the basal dynamics of the p53-pathway and of apoptosis. From Figures 9A to 9C,
clearly the normal response of the system to strong DNA damage is a series of oscillations of
p53 concentration, i.e., a limit cycle dynamics that induces the activation of caspases-3 if the
oscillations last for time enough. However, Mdm2 overexpression suppresses the p53 oscilla‐
tions (Figures 9D to 9F) and avoids cascapse-3 activation (see Section 2.1), allowing the survival
of cells with strong DNA damage. This could be one of the possible dynamical forms in which
cells with intense DNA damage loss the control of apoptosis and survive, leading to a
malignant tumor.
4.4. Suppression of caspase-9
Caspase-9 is a key protease that is constitutively expressed in a variety of fetal and adult tissues.
Previous studies on cancer risk [58] show that polymorphism of caspase-9 is strongly corre‐
lated with lung cancer development in light smokers, reflecting an intense gene-environment
interaction at this level of the apoptotic pathway. The loss of this caspase interrupts apoptosis,
leading to abnormal proliferation of cells with severe DNA damage.
In the model of the p53 pathway, the missing of caspase-9 gene is modeled, assuming that
[ ]d C
dt
9 * 0= (26)
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Results from the minimal model presented in Section 5.1, modified with Equation (26), show
that deletions on the caspase-9 gene suppress the activation of the effector caspase-3, uncou‐
pling the p53 dynamics from the caspases activation module. Although the limit cycle in the
p53–Mdm2 phase plane remains, the absence of caspase-9 avoids the activation of caspase-3
and apoptosis even if the DNA damage is severe.
Figure 9. Oncogenic perturbations on the p53 and apoptosis pathways. Normally, when the cell receives severe DNA
damage, the p53 concentration oscillates (A) following a limit cycle dynamics (B), which eventually starts apoptosis
(C). However, overexpression of Mdm2 abrogates the p53 oscillations (D), dampens the normal dynamics (E), and
avoids the caspase-3 activation (F). On the other hand, deletions on the caspace-9 gene simply abrogate the activation
of effector caspase-3 (I). For all simulations, the time scale is in minutes and concentrations are in micromolar units.
4.5. Survival of malignant cells
These two examples of genetic perturbations show that there are two possible dynamical
mechanisms implicated in the deregulation of apoptosis in cancerous cells. Such mechanisms
are (1) uncoupling between the p53–Mdm2 limit cycle (pacemaker) and the caspase cascade
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and (2) suppression of p53 activity by overexpression of a negative regulator (like Mdm2) that
leads to the not activation of caspase-3.
Figure 10. Variation of the rate of p53 degradation due to Mdm2 repression (k1). Compared with the normal cell re‐
sponse to severe DNA damage (A, B, and C), the effect of decreasing in two orders the rate of p53 degradation due to
Mdm2 k1 augments the magnitude of p53 oscillations (D), preserving its limit cycle (E) and starts quicker apoptosis (F).
On the other hand, the effect of increasing k1 in two orders reduces the magnitude of p53 oscillations (G), avoiding
caspase activation (I) but preserves the limit cycle (H).
In fact, p53 inhibition decreases miR-34a and BTG3 levels, releasing the inhibition on the
activator E2fs and promoting the proliferation of abnormal cells [4]. Thus, a perturbed
functioning of the network may give rise to the malignant transformation of damaged cells.
Besides genetic predisposition, there are other factors that contribute in transforming defective
cells, such as viral and bacterial infections, metabolic disorders, and exposure to toxic sub‐
stances. These exogenous agents modify the global behavior of the p53 network by targeting
strategic interactions like (1) p53 repression due to Mdm2 (represented by k1), (2) the rate of
Mdm2 degradation (represented in the model by δ 3), (3) the rate of Bax releasing (represented
Evolution of Ionizing Radiation Research24
by k2), and (4) the rate of caspase-9 activation (represented by k3). In order to observe the effect
of alterations on these interactions, the corresponding parameters were varied in two orders
of magnitude, and then the stability of the net was studied.
Figure 11. Variation of the basal degradation of Mdm2 (δ3). Compared with the normal cell response to severe DNA
damage (A, B, and C), the effect of increasing in two orders the basal degradation of Mdm2 δ3 abrogates p53 oscilla‐
tions (D), as well as its limit-cycle (E), avoiding apoptosis (F). However, the effect of decreasing δ3 in two orders aug‐
ments the magnitude of p53 concentration (G), making quicker the activation of apoptosis (I) but destroys the limit
cycle dynamics (H). For all simulations, the time scale is in minutes and concentrations are in micromolar units.
The model shows that decreasing k1 allows a faster induction of apoptosis in damaged cells
(Figures 10D to 10F). In biological terms, this effect can be produced when damaged cells are
treated with nutlin-3 [86] and proteins of the influenza A virus [87]. Moreover, augments on
k1 avoid apoptosis triggering (Figures 10G to 10I). In the nature, blocking such an interaction
is a common strategy used by pathogens like Epstein–Barr virus [88] and Chlamydia [89] in
order to ensure their replication inside the host.
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According to previous results, the increase of δ 3 makes the cell more sensitive to DNA damage,
allowing a quicker activation of apoptosis (Figures 11D to 11F). At the molecular level, this
effect can be obtained by augmenting p14ARF activity [90], using substances like capsaicin
[91], or viral proteins like hepatitis C [92]. Another way to achieve this effect is destabilizing
Mdm2 protein by affecting NEDD-4-1 functioning [93]. On the other hand, reducing δ 3
destroys Hopf bifurcation on p53–Mdm2 interaction, blocking definitively the initiation of
apoptosis (Figures 11G to 11I).
Figure 12. Variation of the rate of Bax releasing due to p53 activity (k2). Compared with the normal cell response to
severe DNA damage (A, B, and C), the effect of decreasing in two orders the rate of Bax releasing due to p53 activity k2
does not interfere with the normal behavior of p53 (D), as well as its limit-cycle (E), but avoids apoptosis activation (F).
Furthermore, the effect of increasing k2 in two orders only accelerates the activation of apoptosis (I). For all simulations,
the time scale is in minutes and concentrations are in micromolar units.
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According to the model, when the rate of Bax releasing (k2) increases, the cell is more sensitive
to genotoxic damage as is observed in cells that overexpress Bax [94] (Figures 12G to 12I).
However, when k2 is reduced, the cell lacks its damage responsiveness (Figures 12D to 12F).
Paradoxically, decreasing in k3 has no significant effect on caspase-3 activation (Figures 13D
to 13F). This phenomenon can be explained by the fact that there are many bistable switches
on caspase cascade, sustained by positive feedback loops [59]. Thus, when those alterations
are maintained for long time, the cell tends to accumulate several mutations that destabilize
its genome, which eventually allows its transformation into a tumor cell.
Figure 13. Variation of the rate of procaspase-9 activation (k3). Compared with the normal cell response to severe DNA
damage (A, B, and C), the effect of decreasing in two orders the rate of procaspase-9 activation k3 does not interfere
with the normal behavior of p53 (D), its limit-cycle (E), and apoptosis activation (F). However, the effect of increasing
k3 in two orders only increases slightly apoptosis activation (I). For all simulations, the time scale is in minutes, and
concentrations are in micromolar units.
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5. Therapeutics approaches against cancer
Treatments against all types of cancer aim to interfere the functioning of transformed cells.
Traditionally, this interference was induced by using drugs that block the cell growth together
with radiotherapy [95, 96]. This approach has been the most successful; however, produces
serious collateral effects on patients.
For this motive, in recent years, the use of more selective drugs for inducing apoptosis in
cancerous cells has been proposed. These drugs comprise inhibitors of IAPs, BCL2, Mdm2,
p53, and constitutive activators of death receptors [97–100]. Similarly, another new type of
drugs derived from extract of Emilia sonchifolia has been used to activate caspases through the
induction of reactive oxygen species (ROS) [101]. Polyphenolic curcumin is another promising
natural compound that is capable to trigger apoptosis by increasing the expression and
clustering of FasR in tumor cells. Another approach is based on the construction of nanopar‐
ticles that transport anticancerous compounds to tumor cells [102]. Moreover, more revolu‐
tionary approaches to treat cancer use phototherapy, which consists in administrate of
nontoxic drugs known as “photosensitizers” to cancerous cells. After that, cells receive
posterior illumination of visible light at specific wavelength, triggering the activation of
photosensitizers that produce high amounts of ROS to eliminate the tumor cells by apoptosis
[103].
Another novel approach to treat cancer is gene therapy, which uses many genes to alter the
functioning of transformed cells blocking survival mechanisms and triggering apoptosis [1,
96, 104]. Other original strategies related with gene therapy use micro-RNA specifically
designed to avoid the overexpression of oncogenes like BCL2 family or p53 in cancerous cells
[105, 106].
In addition to gene therapy, the use of cytokines to treat cancer as an effective approach was
proposed because there are reports indicating that the cancer cell lines treated with TNFα have
an increase in DR5 as well of interferon-γ and interferon-α [95]. It has been suggested that the
utilization of some hormones like estrogen in controlled doses can be used as a treatment
because it was reported that cancer breast cells exposed to high doses of estrogen died by
apoptosis [107].
The multiple origins of cancer are the main obstacle for all of these approaches. In order to
show the importance of this point on cancer treatment, the model of apoptosis for simulating
two groups of cancerous cells is used. Both groups overexpress IAPs, but the second group
also has an important deletion on caspase-3 gene. Mathematically, for both groups, Equation
(24) of model 5.1 are modified by adding an oncogenic perturbation parameter (ε onco) to
overexpress IAPs [108] as follows:
I k B It onco 3
d *d e
é ùë û é ù é ù= - ë û ë û (27)
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For simulating caspase-3 deletion in the second group of cancerous cells, Equation (24) must
be modified as follows:
C
t
d 3 * 0d =
é ùë û (28)
With respect to their phenotype, both groups of cells look very similar, and neither the
oncogenic perturbation nor the deletion of caspase-3 interferes with the Hopf bifurcation on
p53–Mdm2 feedback loop (Figures 14A to 14C).
Figure 14. The subclonal heterogeneity as a therapeutics challenge. Cancerous cells that have deletions on the cas‐
pase-3 gene and/or overexpress IAPs present the same phenotype, and dynamically such mutations do not affect the
p53 behavior when the cell receives severe DNA damage (A, B) but avoid apoptosis initiation (C). When cancerous
cells that overexpress IAPs are treated with an inhibitor of IAPs activity and radiotherapy, the apoptosis starts normal‐
ly (F). However, this approach does not work with cells that lack caspase-3 gene (I). For all simulations, the time scale
is in minutes and concentrations are in micromolar units.
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The effect of treatments on both cells groups with drugs that inhibit IAPs together with
radiotherapy is represented as follows:
d
I k B I k D It onco 3
d *d e= - -
é ùë û é ùé ù é ùé ùë ûë û ë ûë û (29)
where kd is the rate of IAPs repression due to inhibitor drugs, represented by [D]. After the
theoretical treatment, the model shows that the first type of cancerous cells is successfully
eliminated by apoptosis (Figures 14D to 14F) but not the second one (Figures 14G to 14I).
Clinically, this problem is known as subclonal heterogeneity [109] and is very common to
several types of tumors, in which transformed cells have many different damages, and thus,
they do not response equally to treatments.
One way to overcome this problem is testing hypothesis and planning strategies to manipulate
the cell functioning with mathematical models. For example, nowadays, it is possible design‐
ing genetic programs with specific functions like self-regulatory systems to attack cancerous
cells [110].
6. Conclusions
The p53–Mdm2 module has a central role to prevent the development of tumor cells. This
module has different modes of operation, depending upon the degree o DNA damage by
pathogens, chemicals, or genotoxic signals. When DNA damage is severe, p53–Mdm2 takes
the control of the apoptotic pathway by activating Bax, which in turn switches on the caspase
cascade. From a dynamical point of view, this process implies the coupling of a supercritical
Hopf bifurcation produced in the nucleus, with a saddle-node bifurcation produced in the
cytoplasm that induces bistability in Bax [111], and caspases activation [59]. Thus, even if the
DNA damage signal is intense, the p53–Mdm2 oscillatory dynamics must sustain enough time
to increase Bax concentration to a threshold value that initiates apoptosis in an irreversible
form; otherwise, the damaged cell can survive.
Mdm2 overexpression disrupts the p53–Mdm2 limit cycle in the nucleus blocking the trans‐
mission of the death signal to the caspase cascade, allowing the survival of the mutated cell.
The suppression of caspase-9 gene causes the uncoupling of the p53–Mdm2 limit cycle and
the caspase cascade, leading to the survival of the mutated cell despite that the DNA damage
signal activates the p53 mechanism of damage suppression. Accordingly, mutated cells can
escape from apoptosis when mutations in cells either disrupt the p53–Mdm2 limit cycle or
uncouple it from the caspase cascade.
As a consequence, tumor cells can arise when they can overcome the apoptotic pathway by
different mechanisms, leading to different strategies for their survival [110]. This variety in the
causes that can originate and allow the survival of transformed cells is one of the obstacles to
find a definitive cure for cancer. The combination of treatments seems to be the best strategy
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against cancer at the moment. Mathematical models of different aspects of cancer can be a
guidance to find betters strategies to optimize and design novel treatments against cancer.
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